Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
NCT06500208
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide
Sponsor
Shanghai Jiao Tong University School of Medicine